N-Acetyl Selank Amidate
Also known as: Enhanced Selank, Stabilized Selank, NASA (N-Acetyl Selank Amidate)
Evidence: Anecdotal
Overview
Acetylated, amidated analog of Selank, a tuftsin-derived heptapeptide; Russian research on the parent peptide reports anxiolytic and mild nootropic effects without sedation.
N-Acetyl Selank Amidate is a terminally modified analog of Selank, itself a synthetic analog of the immunopeptide tuftsin. Russian studies of the parent peptide report anxiolytic effects attributed to GABAergic and serotonergic modulation, plus enkephalinase inhibition and immunomodulatory (IL-6, interferon) effects, without the sedation or dependence of benzodiazepines. The acetylated-amidated analog has no published trials of its own; greater stability and potency are inferred from its chemistry and reported by users.
Benefits
Cognitive support, anxiolytic
Dosing reference
- Research dose
- Vendor/community range 250 to 500 mcg once or twice daily, intranasal; no published human or animal dose for this analog.
- Range
- 250 to 500 mcg, 1-2x daily
- Reconstitution
- 2 mL bacteriostatic water
- Common vial sizes
- 5 mg
Intranasal per vendors. No pharmacology has been published for the acetylated, amidated analog; data for the parent Selank do not transfer automatically.
Mechanism
No pharmacology of the acetylated, amidated form is published; claims of better stability, absorption or potency are extrapolation. For unmodified Selank, Russian work reports inhibition of enkephalin-degrading enzymes (Zozulya et al., 2001), changes in GABAergic gene expression in rodent brain (Volkova et al., 2016) and raised hippocampal BDNF after intranasal dosing in rats (Inozemtseva et al., 2008).
Evidence
Anecdotal: no peer-reviewed data
- No study of N-acetyl Selank amidate in any species has been published
- Unmodified Selank was studied as an anxiolytic in a Russian trial in generalized anxiety disorder and neurasthenia (n=62) (Zozulia et al., 2008)
- Unmodified Selank is reviewed as a heptapeptide anxiolytic with several proposed molecular targets (Vyunova et al., 2018)
- Human-trial status: none for this analog. Unmodified Selank is a registered drug in Russia (Deigin et al., 2022); that registration does not extend to the modified form
References
- Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia. Zozulia AA, Neznamov GG, Siuniakov TS, et al., Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova, 2008
- Peptide-based Anxiolytics: The Molecular Aspects of Heptapeptide Selank Biological Activity. Vyunova TV, Andreeva L, Shevchenko K, et al., Protein & Peptide Letters, 2018
- The inhibitory effect of Selank on enkephalin-degrading enzymes as a possible mechanism of its anxiolytic activity. Zozulya AA, Kost NV, Yu Sokolov O, et al., Bulletin of Experimental Biology and Medicine, 2001
- Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission. Volkova A, Shadrina M, Kolomin T, et al., Frontiers in Pharmacology, 2016
- Intranasal administration of the peptide Selank regulates BDNF expression in the rat hippocampus in vivo. Inozemtseva LS, Karpenko EA, Dolotov OV, et al., Doklady Biological Sciences, 2008
- Development of Peptide Biopharmaceuticals in Russia. Deigin VI, Poluektova EA, Beniashvili AG, et al., Pharmaceutics, 2022
Side effects
Nasal irritation, mild drowsiness, and occasional dizziness are the reported effects. Safety data for this modified analog specifically is limited; the available evidence comes from unmodified Selank in Russian trials.
Storage
- Storage
- Refrigerate 2-8°C (36-46°F)
- Lyophilized
- 2+ years at room temp, 3+ years refrigerated
- Reconstituted
- 28-30 days refrigerated
Pharmacology
- Half-life
- Not measured in any species
- Bioavailability
- Not measured in any species
- Molecular weight
- 793 Da
- Sequence
- Ac-Thr-Lys-Pro-Arg-Pro-Gly-Pro-NH2 (N-acetyl, C-amide)